The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium

被引:87
作者
Quast, U [1 ]
Stephan, D [1 ]
Bieger, S [1 ]
Russ, U [1 ]
机构
[1] Univ Tubingen, Dept Pharmacol & Toxicol, Fac Med, D-72074 Tubingen, Germany
关键词
D O I
10.2337/diabetes.53.suppl_3.S156
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Insulin secretagogues (sulfonylureas and glinides) increase insulin secretion by closing the ATP-sensitive K(+) channel (K(ATP) channel) in the pancreatic beta-cell membrane. K(ATP) channels subserve important functions also in the heart. First, K(ATP) channels in coronary myocytes contribute to the control of coronary blood flow at rest and in hypoxia. Second, K(ATP) channels in the sarcolemma of cardiomyocytes (sarcK(ATP) channels) are required for adaptation of the heart to stress. In addition, the opening of sarcK(ATP) channels and of K(ATP) channels in the inner membrane of mitochondria (mitoK(ATP) channels) plays a central role in ischemic preconditioning. Opening of sarcK(ATP) channels also underlies the ST-segment elevation of the electrocardiogram, the primary diagnostic tool for initiation of lysis therapy in acute myocardial infarction. Therefore, inhibition of cardiovascular K(ATP) channels by insulin secretagogues is considered to increase cardiovascular risk. Electrophysiological experiments have shown that the secretagogues differ in their selectivity for the pancreatic over the cardiovascular K(ATP) channels, being either highly selective (similar to1,000X; short sulfonylureas such as nateglinide and mitiglinide), moderately selective (10-20x; long sulfonylureas such as glibenclamide [glyburide]), or essentially nonselective (<2x; repaglinide). New binding studies presented here give broadly similar results. In clinical studies, these differences are not yet taken into account. The hypothesis that the in vitro selectivity of the insulin secretagogues is of importance for the cardiovascular outcome of diabetic patients with coronary artery disease needs to be tested.
引用
收藏
页码:S156 / S164
页数:9
相关论文
共 58 条
[1]   Molecular biology of adenosine triphosphate-sensitive potassium channels [J].
Aguilar-Bryan, L ;
Bryan, J .
ENDOCRINE REVIEWS, 1999, 20 (02) :101-135
[2]   Incidence of new coronary events in older persons with diabetes mellitus and prior myocardial infarction treated with sulfonylureas, insulin, metformin, and diet alone [J].
Aronow, WS ;
Ahn, C .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (05) :556-+
[3]   Identification of the high-affinity tolbutamide site on the SUR1 subunit of the KATP channel [J].
Ashfield, R ;
Gribble, FM ;
Ashcroft, SJH ;
Ashcroft, FM .
DIABETES, 1999, 48 (06) :1341-1347
[4]   ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic KATP channel gating [J].
Bienengraeber, M ;
Olson, TM ;
Selivanov, VA ;
Kathmann, EC ;
O'Cochlain, F ;
Gao, F ;
Karger, AB ;
Ballew, JD ;
Hodgson, DM ;
Zingman, LV ;
Pang, YP ;
Alekseev, AE ;
Terzic, A .
NATURE GENETICS, 2004, 36 (04) :382-387
[5]   S-T segment voltage during sequential coronary occlusions is an unreliable marker of preconditioning [J].
Birincioglu, M ;
Yang, XM ;
Critz, SD ;
Cohen, MV ;
Downey, JM .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1999, 277 (06) :H2435-H2441
[6]   The sulfonylurea controversy - Much ado about nothing or cause for concern? [J].
Brady, PA ;
Jovanovic, A .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (06) :1022-1025
[7]   Functional roles of KATP channels in vascular smooth muscle [J].
Brayden, JE .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2002, 29 (04) :312-316
[8]   RECEPTOR-BINDING SITES OF HYPOGLYCEMIC SULFONYLUREAS AND RELATED [(ACYLAMINO)ALKYL]BENZOIC ACIDS [J].
BROWN, GR ;
FOUBISTER, AJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1984, 27 (01) :79-81
[9]   Adenylate kinase phosphotransfer communicates cellular energetic signals to ATP-sensitive potassium channels [J].
Carrasco, AJ ;
Dzeja, PP ;
Alekseev, AE ;
Pucar, D ;
Zingman, LV ;
Abraham, MR ;
Hodgson, D ;
Bienengraeber, M ;
Puceat, M ;
Janssen, E ;
Wieringa, B ;
Terzic, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (13) :7623-7628
[10]   Nateglinide, a D-phenylalanine derivative lacking either a sulfonylurea or benzamido moiety, specifically inhibits pancreatic β-cell-type KATP channels [J].
Chachin, M ;
Yamada, M ;
Fujita, A ;
Matsuoka, T ;
Matsushita, K ;
Kurachi, Y .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 304 (03) :1025-1032